Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | LPO | P22079 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7707893 | 0.81 | TAAR1 (0.61) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL227516 | 0.81 | TAAR1 (0.59) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL5251257 | 0.81 | TAAR1 (0.55) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL467238 | 0.79 | ALDH1A1 (0.50) | — | |
| SCHEMBL11154358 | 0.79 | CHRM2 (0.58) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL5251988 | 0.79 | KMT2A (0.47) | — | |
| SCHEMBL17743 | 0.78 | TAAR1 (0.60) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL29351751 | 0.78 | TAAR1 (0.60) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL5252614 | 0.78 | DHFR (0.48) | — | |
| SCHEMBL723511 | 0.77 | TAAR1 (0.77) | TAAR1IDO1AGXTCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| US-20260132149-A1 | Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith | BEONE MEDICINES I GMBH (CH) | 2026-05-14 | — | — | US | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-9512126-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-12-06 | — | — | US | disclosed |
| EP-2825540-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| EP-3007698-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-20150104526-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| EP-2825540-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2015-01-21 | — | — | EP | disclosed |
| WO-2014198776-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2011011330-A2 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | Janssen Pharmaceuticals, Inc. | 2007-09-13 | — | — | US | disclosed |
| EP-1799646-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-27 | — | — | EP | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| EP-1690863-A1 | NOVEL CONDENSED IMIDAZOLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006030032-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| US-5939551-A | Process for producing 4a-aryldecahydroisoquinoline derivatives | TORAY INDUSTRIES, INC. (JP) | 1999-08-17 | — | — | US | disclosed |
| US-5852216-A | Preparation and use of (3-alkoxy-phenyl) magnesium chlorides | GRUENENTHAL GMBH (DE) | 1998-12-22 | — | — | US | disclosed |
| EP-0845460-A1 | PROCESS FOR PRODUCING 4a-ARYLDECAHYDROISOQUINOLINE DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1998-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | TAAR1 1903/4885IDO1 817/4885AGXT 726/4885 |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | TAAR1 220/4885IDO1 976/4885AGXT 2974/4885 |
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BUB1, BUB1B, CDK1 | TAAR1 3174/4885IDO1 2034/4885AGXT 4023/4885 |
| US-20260132149-A1 | Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith | MECP2, PRMT5, DNMT1 | TAAR1 3730/4885IDO1 3024/4885AGXT 3877/4885 |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, ACHE | TAAR1 1412/4885IDO1 694/4885AGXT 132/4885 |
| US-20150104526-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | VEGFA, CCND2, FLT4 | TAAR1 4590/4885IDO1 419/4885AGXT 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.